Theravance Biopharma reports on biomarker data from phase 1 study
March 9, 2016 – DUBLIN. Theravance Biopharma, Inc. announced positive results, including positive biomarker data, from its Phase 1 single-ascending dose (SAD) clinical trial of TD-0714, the lead molecule in the Company’s neprilysin (NEP) inhibitor program for the treatment of a range of major cardiovascular and renal diseases.
The trial in healthy volunteers was designed to assess the safety, tolerability and pharmacokinetics of TD-0714, as well as measure biomarker evidence of target engagement and the amount of the drug that is eliminated via the kidneys.
Key study findings included the following:
These results met the Company’s target product profile and provide confidence for future efficacy studies of TD-0714 in a broad range of cardiovascular and renal diseases, including in patients with compromised renal function. Theravance Biopharma is now conducting a Phase 1 multiple-ascending dose (MAD) study of TD-0714 that is designed to supplement the findings of the SAD study and support the ongoing clinical development of the molecule. The Company expects to complete the MAD study in the second half of this year.
“We are very encouraged by the data from this first clinical study of TD-0714. The data show a favorable safety and tolerability profile, dose-dependent kinetics and robust biomarker evidence of NEP inhibition that is sustained over 24 hours, supporting the potential for once-daily dosing. We were particularly pleased to see insignificant levels of renal clearance of TD-0714. The molecule is not dependent on the kidney for its elimination, therefore, it will not be necessary to adjust the dose in patients with low or variable renal function, in contrast to existing NEP-inhibitor-based therapy. This is important because a significant number of patients with cardiac and renal disease who may benefit from NEP inhibition have compromised renal function,” said Brett Haumann, MD, Chief Medical Officer at Theravance Biopharma. “Furthermore, TD-0714 has the potential to be combined with a range of other therapies, including angiotensin receptor blockers and therapies with complimentary mechanisms of action, to treat patients with a range of cardiovascular and renal diseases.”
“We set out to meet the difficult and specific challenge of designing a novel, once-daily, oral compound capable of clinically meaningful NEP inhibition with virtually no elimination of the drug through the kidneys,” said Sharath S. Hegde, Ph.D., Senior Vice President, Research. “The data from this initial trial of TD-0714 provide clear evidence that we have achieved our goal and created a compound that possesses each of these critical attributes.”
The Phase 1 clinical trial of TD-0714 was a randomized, double-blind, placebo-controlled, single-ascending dose study. The study investigated the safety and tolerability, pharmacokinetics, and pharmacodynamics of five ascending oral doses of TD-0714 (50, 100, 200, 400, and 600 mg) in 56 healthy volunteers.
About Neprilysin (NEP) Inhibition
Neprilysin (NEP) is an enzyme that degrades natriuretic peptides. These peptides exert protective cardiac and renal effects including vasodilation, diuresis, natriuresis, reversal of maladaptive changes in heart, blood vessels and kidney, prevention of fibrosis, and prevention of end-organ damages. By elevating levels of natriuretic peptides, NEP inhibitors may have the potential to treat a range of major cardiovascular and renal diseases, including acute and chronic heart failure and chronic kidney disease. Roughly 26 million Americans suffer from chronic kidney disease, including diabetic nephropathy. In the U.S. alone, there are six million patients diagnosed with chronic heart failure and approximately one million hospitalizations annually for acute heart failure.
Source: Theravance Biopharma, Inc